Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
17 percent of patients seeing neurologist travel long distance
Sep 13, 2023
Factors associated with long-distance travel include low neurologist density, rural setting and visits for ALS and nervous system cancer.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Medicare monthly premiums to drop for seniors
Sep 28, 2022
The fee cuts come at the same time as seniors receive a Social Security cost-of-living increase for 2023 of up to 9 or 10%.
Medicare spending spikes for dementia diagnoses in seniors
Jun 13, 2022
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
Medicare policy changes tied to drop in hospice use for dementia
May 09, 2022
Immediate and lasting reductions were seen in the share of patients receiving hospice care with the Alzheimer’s disease and related dementia code.
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
Alzheimer’s disease, related dementia diagnoses up in Medicare decedents
Apr 01, 2022
The percentage of older U.S. decedents with a diagnosis of Alzheimer’s disease and related dementias increased significantly from 2004 to 2017.